315 related articles for article (PubMed ID: 25928015)
21. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
22. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.
Bessho Y; Oguri T; Achiwa H; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Cancer Sci; 2006 Mar; 97(3):192-8. PubMed ID: 16542215
[TBL] [Abstract][Full Text] [Related]
23. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
[TBL] [Abstract][Full Text] [Related]
24. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Inoue Y; Ikegami Y; Sano K; Suzuki T; Yoshida H; Nakamura Y; Nakagawa H; Ishikawa T
Chemotherapy; 2013; 59(4):260-72. PubMed ID: 24457609
[TBL] [Abstract][Full Text] [Related]
27. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
28. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
29. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
30. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
Yoshikawa M; Ikegami Y; Sano K; Yoshida H; Mitomo H; Sawada S; Ishikawa T
J Exp Ther Oncol; 2004 Apr; 4(1):25-35. PubMed ID: 15255290
[TBL] [Abstract][Full Text] [Related]
31. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
32. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?
Li F; Ling X; Harris DL; Liao J; Wang Y; Westover D; Jiang G; Xu B; Boland PM; Jin C
Am J Cancer Res; 2017; 7(2):370-382. PubMed ID: 28337384
[TBL] [Abstract][Full Text] [Related]
34. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
[TBL] [Abstract][Full Text] [Related]
35. FL118, a novel camptothecin analogue, suppressed migration and invasion of human breast cancer cells by inhibiting epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.
Yang Z; Ji L; Jiang G; Liu R; Liu Z; Yang Y; Ma Q; Zhao H
Biosci Trends; 2018; 12(1):40-46. PubMed ID: 29553100
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
[TBL] [Abstract][Full Text] [Related]
38. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Chang CH; Wang Y; Zalath M; Liu D; Cardillo TM; Goldenberg DM
Mol Cancer Ther; 2016 Aug; 15(8):1910-9. PubMed ID: 27207776
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
[TBL] [Abstract][Full Text] [Related]
40. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
